975 results on '"Yang, Ju Dong"'
Search Results
2. Clinical Characteristics and Outcomes of Nonalcoholic Fatty Liver Disease-Associated Hepatocellular Carcinoma in the United States.
- Author
-
Karim, Mohammad, Singal, Amit, Kum, Hye, Lee, Yi-Te, Park, Sulki, Rich, Nicole, Noureddin, Mazen, and Yang, Ju Dong
- Subjects
Liver Cancer ,NAFLD ,NASH ,Surveillance ,Humans ,Aged ,United States ,Carcinoma ,Hepatocellular ,Non-alcoholic Fatty Liver Disease ,Liver Neoplasms ,Medicare - Abstract
BACKGROUND & AIMS: The extent to which nonalcoholic fatty liver disease (NAFLD) contributes to hepatocellular carcinoma (HCC) prevalence in contemporary practices and whether there are any etiologic differences in surveillance receipt, tumor stage, and overall survival (OS) remain unclear. We aimed to estimate the burden of NAFLD-related HCC and magnitude of associations with surveillance receipt, clinical presentation, and outcomes in a contemporary HCC cohort. METHODS: In a cohort of HCC patients from the Surveillance, Epidemiology and End Results-Medicare database between 2011 and 2015, we used multivariable logistic regression to identify factors associated with surveillance receipt, early-stage tumor detection, and curative treatment. Cox regression was used to identify factors associated with OS. RESULTS: Among 5098 HCC patients, NAFLD was the leading etiology, accounting for 1813 cases (35.6%). Compared with those with hepatitis C-related HCC, NAFLD was associated with lower HCC surveillance receipt (adjusted odds ratio, 0.22; 95% confidence interval [CI], 0.17-0.28), lower early-stage HCC detection (adjusted odds ratio, 0.49; 95% CI, 0.40-0.60), and modestly worse OS (adjusted hazard ratio, 1.20; 95% CI, 1.09-1.32). NAFLD subgroup analysis showed that early-stage HCC, absence of ascites/hepatic encephalopathy, surveillance, and curative treatment receipt were associated with improved OS. NAFLD patients with coexisting liver disease were more likely to have surveillance, early-stage detection, curative treatment, and improved OS than NAFLD patients without coexisting liver diseases. CONCLUSIONS: NAFLD is the leading etiology of HCC among Medicare beneficiaries. Compared with other etiologies, NAFLD was associated with lower HCC surveillance receipt, early-stage detection, and modestly poorer survival. Multifaceted interventions for improving surveillance uptake are needed to improve prognosis of patients with NAFLD-related HCC.
- Published
- 2023
3. HCC EV ECG score: An extracellular vesicle‐based protein assay for detection of early‐stage hepatocellular carcinoma
- Author
-
Sun, Na, Zhang, Ceng, Lee, Yi‐Te, Tran, Benjamin V, Wang, Jing, Kim, Hyoyong, Lee, Junseok, Zhang, Ryan Y, Wang, Jasmine J, Hu, Junhui, Zhang, Zhicheng, Alsudaney, Manaf S, Hou, Kuan‐Chu, Tang, Hubert, Zhang, Tiffany X, Liang, Icy Y, Zhou, Ziang, Chen, Mengxiang, Yeh, Angela Hsiao‐Jiun, Li, Wenyuan, Zhou, Xianghong Jasmine, Chang, Helena R, Han, Steven‐Huy B, Sadeghi, Saeed, Finn, Richard S, Saab, Sammy, Busuttil, Ronald W, Noureddin, Mazen, Ayoub, Walid S, Kuo, Alexander, Sundaram, Vinay, Al‐Ghaieb, Buraq, Palomique, Juvelyn, Kosari, Kambiz, Kim, Irene K, Todo, Tsuyoshi, Nissen, Nicholas N, Tomasi, Maria Lauda, You, Sungyong, Posadas, Edwin M, Wu, James X, Wadehra, Madhuri, Sim, Myung‐Shin, Li, Yunfeng, Wang, Hanlin L, French, Samuel W, Lu, Shelly C, Wu, Lily, Pei, Renjun, Liang, Li, Yang, Ju Dong, Agopian, Vatche G, Tseng, Hsian‐Rong, and Zhu, Yazhen
- Subjects
Biomedical and Clinical Sciences ,Oncology and Carcinogenesis ,Liver Cancer ,Prevention ,Liver Disease ,Cancer ,Clinical Research ,Digestive Diseases ,Rare Diseases ,4.2 Evaluation of markers and technologies ,4.1 Discovery and preclinical testing of markers and technologies ,Detection ,screening and diagnosis ,Good Health and Well Being ,Humans ,Carcinoma ,Hepatocellular ,Liver Neoplasms ,Biomarkers ,Tumor ,Extracellular Vesicles ,Membrane Proteins ,Electrocardiography ,Glypicans ,Medical Biochemistry and Metabolomics ,Clinical Sciences ,Immunology ,Gastroenterology & Hepatology ,Clinical sciences - Abstract
Background and aimsThe sensitivity of current surveillance methods for detecting early-stage hepatocellular carcinoma (HCC) is suboptimal. Extracellular vesicles (EVs) are promising circulating biomarkers for early cancer detection. In this study, we aim to develop an HCC EV-based surface protein assay for early detection of HCC.Approach and resultsTissue microarray was used to evaluate four potential HCC-associated protein markers. An HCC EV surface protein assay, composed of covalent chemistry-mediated HCC EV purification and real-time immuno-polymerase chain reaction readouts, was developed and optimized for quantifying subpopulations of EVs. An HCC EV ECG score, calculated from the readouts of three HCC EV subpopulations ( E pCAM + CD63 + , C D147 + CD63 + , and G PC3 + CD63 + HCC EVs), was established for detecting early-stage HCC. A phase 2 biomarker study was conducted to evaluate the performance of ECG score in a training cohort ( n = 106) and an independent validation cohort ( n = 72).Overall, 99.7% of tissue microarray stained positive for at least one of the four HCC-associated protein markers (EpCAM, CD147, GPC3, and ASGPR1) that were subsequently validated in HCC EVs. In the training cohort, HCC EV ECG score demonstrated an area under the receiver operating curve (AUROC) of 0.95 (95% confidence interval [CI], 0.90-0.99) for distinguishing early-stage HCC from cirrhosis with a sensitivity of 91% and a specificity of 90%. The AUROCs of the HCC EV ECG score remained excellent in the validation cohort (0.93; 95% CI, 0.87-0.99) and in the subgroups by etiology (viral: 0.95; 95% CI, 0.90-1.00; nonviral: 0.94; 95% CI, 0.88-0.99).ConclusionHCC EV ECG score demonstrated great potential for detecting early-stage HCC. It could augment current surveillance methods and improve patients' outcomes.
- Published
- 2023
4. Recall patterns and risk of primary liver cancer for subcentimeter ultrasound liver observations: a multicenter study.
- Author
-
Singal, Amit G, Ghaziani, T Tara, Mehta, Neil, Zhou, Kali, Grinspan, Lauren T, Benhammou, Jihane N, Moon, Andrew M, Yang, Ju Dong, Salgia, Reena, Pillai, Anjana, Zheng, Elizabeth, Rich, Nicole E, Gopal, Purva, Jalal, Prasun, Verna, Elizabeth, Yekkaluri, Sruthi, Phen, Samuel, Melendez-Torres, Jonathan, Alshuwaykh, Omar, Choi, Hailey, Junus, Kevin, Grady, John, Song, Michael, Leven, Emily A, Yum, Jung, Gowda, Vrushab, Alsudaney, Manaf, Hernandez, Perla, Desai, Nirmal, and Parikh, Neehar D
- Subjects
Bile Ducts ,Intrahepatic ,Humans ,Carcinoma ,Hepatocellular ,Bile Duct Neoplasms ,Liver Neoplasms ,Liver Cirrhosis ,alpha-Fetoproteins ,Retrospective Studies ,Digestive Diseases ,Biomedical Imaging ,Cancer ,Clinical Research ,Liver Disease ,Prevention ,Hepatitis ,Liver Cancer ,Chronic Liver Disease and Cirrhosis ,Rare Diseases ,Good Health and Well Being - Abstract
BackgroundPatients with cirrhosis and subcentimeter lesions on liver ultrasound are recommended to undergo short-interval follow-up ultrasound because of the presumed low risk of primary liver cancer (PLC).AimsThe aim of this study is to characterize recall patterns and risk of PLC in patients with subcentimeter liver lesions on ultrasound.MethodsWe conducted a multicenter retrospective cohort study among patients with cirrhosis or chronic hepatitis B infection who had subcentimeter ultrasound lesions between January 2017 and December 2019. We excluded patients with a history of PLC or concomitant lesions ≥1 cm in diameter. We used Kaplan Meier and multivariable Cox regression analyses to characterize time-to-PLC and factors associated with PLC, respectively.ResultsOf 746 eligible patients, most (66.0%) had a single observation, and the median diameter was 0.7 cm (interquartile range: 0.5-0.8 cm). Recall strategies varied, with only 27.8% of patients undergoing guideline-concordant ultrasound within 3-6 months. Over a median follow-up of 26 months, 42 patients developed PLC (39 HCC and 3 cholangiocarcinoma), yielding an incidence of 25.7 cases (95% CI, 6.2-47.0) per 1000 person-years, with 3.9% and 6.7% developing PLC at 2 and 3 years, respectively. Factors associated with time-to-PLC were baseline alpha-fetoprotein >10 ng/mL (HR: 4.01, 95% CI, 1.85-8.71), platelet count ≤150 (HR: 4.90, 95% CI, 1.95-12.28), and Child-Pugh B cirrhosis (vs. Child-Pugh A: HR: 2.54, 95% CI, 1.27-5.08).ConclusionsRecall patterns for patients with subcentimeter liver lesions on ultrasound varied widely. The low risk of PLC in these patients supports short-interval ultrasound in 3-6 months, although diagnostic CT/MRI may be warranted for high-risk subgroups such as those with elevated alpha-fetoprotein levels.
- Published
- 2023
5. Circulating tumor cells: A step toward precision medicine in hepatocellular carcinoma
- Author
-
Teng, Pai‐Chi, Agopian, Vatche G, Lin, Ting‐Yi, You, Sungyong, Zhu, Yazhen, Tseng, Hsian‐Rong, and Yang, Ju Dong
- Subjects
Biomedical and Clinical Sciences ,Oncology and Carcinogenesis ,Liver Disease ,Rare Diseases ,Clinical Research ,Cancer ,Liver Cancer ,Digestive Diseases ,Genetics ,4.2 Evaluation of markers and technologies ,Detection ,screening and diagnosis ,4.1 Discovery and preclinical testing of markers and technologies ,Good Health and Well Being ,Biomarkers ,Biomarkers ,Tumor ,Carcinoma ,Hepatocellular ,Humans ,Liver Neoplasms ,Neoplastic Cells ,Circulating ,Precision Medicine ,Prospective Studies ,biomarker ,circulating tumor cell ,CTC digital scoring ,CTC enumeration ,hepatocellular carcinoma ,Clinical Sciences ,Gastroenterology & Hepatology ,Clinical sciences - Abstract
Serum alpha-fetoprotein and radiologic imaging are the most commonly used tests for early diagnosis and dynamic monitoring of treatment response in hepatocellular carcinoma (HCC). However, the accuracy of these tests is limited, and they may not reflect the underlying biology of the tumor. Thus, developing highly accurate novel HCC biomarkers reflecting tumor biology is a clinically unmet need. Circulating tumor cells (CTCs) have long been proposed as a noninvasive biomarker in clinical oncology. Most CTC assays utilize immunoaffinity-based, size-based, and/or enrichment-free mechanisms followed by immunocytochemical staining to characterize CTCs. The prognostic value of HCC CTC enumeration has been extensively validated. Subsets of CTCs expressing mesenchymal markers are also reported to have clinical significance. In addition, researchers have been devoting their efforts to molecular characterizations of CTCs (e.g. genetics and transcriptomics) as molecular profiling can offer a more accurate readout and provide biological insights. As new molecular profiling techniques, such as digital polymerase chain reaction, are developed to detect minimal amounts of DNA/RNA, several research groups have established HCC CTC digital scoring systems to quantify clinically relevant gene panels. Given the versatility of CTCs to provide intact molecular and functional data that reflects the underlying tumor, CTCs have great potential as a noninvasive biomarker in HCC. Large-scale, prospective studies for HCC CTCs with a standardized protocol are necessary for successful clinical translation.
- Published
- 2022
6. Cholangiocarcinoma — novel biological insights and therapeutic strategies
- Author
-
Ilyas, Sumera I., Affo, Silvia, Goyal, Lipika, Lamarca, Angela, Sapisochin, Gonzalo, Yang, Ju Dong, and Gores, Gregory J.
- Published
- 2023
- Full Text
- View/download PDF
7. Disparities in metabolic dysfunction-associated steatotic liver disease and cardiometabolic conditions in low and lower middle-income countries: a systematic analysis from the global burden of disease study 2019
- Author
-
Danpanichkul, Pojsakorn, Suparan, Kanokphong, Dutta, Priyata, Kaeosri, Chuthathip, Sukphutanan, Banthoon, Pang, Yanfang, Kulthamrongsri, Narathorn, Jaisa-aad, Methasit, Ng, Cheng Han, Teng, Margaret, Nakano, Masahito, Morishita, Asahiro, Alkhouri, Naim, Yang, Ju Dong, Chen, Vincent L., Kim, Donghee, Fallon, Michael B., Diaz, Luis Antonio, Arab, Juan Pablo, Mantzoros, Christos S., Noureddin, Mazen, Lazarus, Jeffrey V., and Wijarnpreecha, Karn
- Published
- 2024
- Full Text
- View/download PDF
8. Hepatocellular carcinoma surveillance: current practice and future directions
- Author
-
Ahn, Joseph C, Lee, Yi-Te, Agopian, Vatche G, Zhu, Yazhen, You, Sungyong, Tseng, Hsian-Rong, and Yang, Ju Dong
- Subjects
Biomedical and Clinical Sciences ,Oncology and Carcinogenesis ,Rare Diseases ,Hepatitis ,Chronic Liver Disease and Cirrhosis ,Cancer ,Digestive Diseases ,Prevention ,Liver Disease ,Infectious Diseases ,Liver Cancer ,Detection ,screening and diagnosis ,4.1 Discovery and preclinical testing of markers and technologies ,Good Health and Well Being ,Hepatocellular carcinoma ,alpha-fetoprotein ,cirrhosis ,hepatitis B virus ,liquid biopsy ,surveillance ,under-utilization - Abstract
Hepatocellular carcinoma (HCC) is among the leading causes of cancer incidence and mortality worldwide. Surveillance of individuals with cirrhosis or other conditions that confer a high risk of HCC development is essential for early detection and improved overall survival. Biannual ultrasonography with or without alpha-fetoprotein is widely recommended as the standard method for HCC surveillance, but it has limited sensitivity in early disease and may be inadequate in certain individuals. This review article will provide a comprehensive overview of the current landscape of HCC surveillance, including the rationale and indications for HCC surveillance, standard methods for HCC surveillance, and their strengths/limitations. Alternative surveillance methods such as the role of cross-sectional imaging, emerging circulating biomarkers, as well as the problem of under-utilization of HCC surveillance and surveillance-related harms will also be discussed in this review.
- Published
- 2022
9. Hepatocellular Carcinoma Surveillance Patterns and Outcomes in Patients With Cirrhosis
- Author
-
Daher, Darine, Seif El Dahan, Karim, Cano, Alva, Gonzales, Michael, Ransom, Crystal, Jaurez, Erik, Carranza, Osiris, Quirk, Lisa, Morgan, Todd, Gopal, Purva, Patel, Madhukar S., Lieber, Sarah, Louissaint, Jeremy, Cotter, Thomas G., VanWagner, Lisa B., Yang, Ju Dong, Parikh, Neehar D., Yopp, Adam, Rich, Nicole E., and Singal, Amit G.
- Published
- 2024
- Full Text
- View/download PDF
10. Impact of pre-transplant immune checkpoint inhibitor use on post-transplant outcomes in HCC: A systematic review and individual patient data meta-analysis
- Author
-
Rezaee-Zavareh, Mohammad Saeid, Yeo, Yee Hui, Wang, Tielong, Guo, Zhiyong, Tabrizian, Parissa, Ward, Stephen C., Barakat, Fatma, Hassanein, Tarek I., Shravan, Dave, Veeral, Ajmera, Bhoori, Sherrie, Mazzaferro, Vincenzo, Chascsa, David M.H., Liu, Margaret C., Aby, Elizabeth S., Lake, John R., Sogbe, Miguel, Sangro, Bruno, Abdelrahim, Maen, Esmail, Abdullah, Schmiderer, Andreas, Chouik, Yasmina, Rudolph, Mark, Sohal, Davendra, Giudicelli, Heloise, Allaire, Manon, Akce, Mehmet, Guadagno, Jessica, Tow, Clara Y., Massoumi, Hatef, De Simone, Paolo, Kang, Elise, Gartrell, Robyn D., Martinez, Mercedes, Paz-Fumagalli, Ricardo, Toskich, Beau B., Tran, Nguyen H., Solino, Gabriela Azevedo, Poltronieri Pacheco, Dra Mariana, Kalman, Richard S., Agopian, Vatche G., Mehta, Neil, Parikh, Neehar D., Singal, Amit G., and Yang, Ju Dong
- Published
- 2024
- Full Text
- View/download PDF
11. Development and Validation of a Noninvasive Model for the Detection of High-Risk Varices in Patients with Unresectable HCC
- Author
-
Parikh, Neehar D., Jones, Patricia, Salgia, Reena, Bhan, Irun, Grinspan, Lauren T., Jou, Janice H., Zhou, Kali, Jalal, Prasun, Roccaro, Giorgio, Rangnekar, Amol S., Benhammou, Jihane N., Pillai, Anjana, Mehta, Neil, Wedd, Joel, Yang, Ju Dong, Kim, Amy K., Duarte-Rojo, Andres, Oloruntoba, Omobonike O., Tevar, Amit, Au, Jennifer S., Blain, Yamile, Rao, Sanjana, Catalano, Onofrio A., Lewis, Sara, Mendiratta-Lala, Mishal, King, Kevin, Sachdev, Lekha, Lee, Edward W., Bruno, Jill, Kamel, Ihab, Tolosa, Celestina, Kao, Karissa, Badawi, Tarek, Przybyszewski, Eric M., Quirk, Lisa, Nathani, Piyush, Haydel, Brandy, Leven, Emily, Wong, Nicole, Albertian, Robert, Chen, Ariana, Aloor, Fuad Z., Mohamed, Islam B., Elkheshen, Ahmed, Marvil, Charles, Issac, Gerard, Clinton, Joseph W., Woo, Stephanie M., Yum, Jung, Rieger, Erin, Hutchison, Alan L., Turner, Don A., Alsudaney, Manaf, Hernandez, Perla, Xu, Ziyi, Khalid, Abdullah, Barrick, Bethany, Wang, Bo, Tapper, Elliot B., Hao, Wei, and Singal, Amit G.
- Published
- 2024
- Full Text
- View/download PDF
12. COVID-19 Pandemic Impact on Diagnosis, Stage, and Treatment of Hepatocellular Carcinoma in the United States
- Author
-
Kaur, Bhupinder, Yeo, Yee Hui, Liang, Jeff, Luu, Michael, Ayoub, Walid, Kuo, Alexander, Trivedi, Hirsh, Sankar, Kamya, Gong, Jun, Hendifar, Andrew, Osipov, Arsen, Kosari, Kambiz, Nissen, Nicholas, Noureddin, Mazen, Singal, Amit G., and Yang, Ju Dong
- Published
- 2024
- Full Text
- View/download PDF
13. The Mortality and Overall Survival Trends of Primary Liver Cancer in the United States
- Author
-
Lee, Yi-Te, Wang, Jasmine J, Luu, Michael, Noureddin, Mazen, Kosari, Kambiz, Agopian, Vatche G, Rich, Nicole E, Lu, Shelly C, Tseng, Hsian-Rong, Nissen, Nicholas N, Singal, Amit G, and Yang, Ju Dong
- Subjects
Biomedical and Clinical Sciences ,Oncology and Carcinogenesis ,Liver Cancer ,Rare Diseases ,Cancer ,Liver Disease ,Aging ,Digestive Diseases ,Good Health and Well Being ,Aged ,Bile Duct Neoplasms ,Bile Ducts ,Intrahepatic ,Carcinoma ,Hepatocellular ,Cholangiocarcinoma ,Humans ,Liver Neoplasms ,United States ,Oncology & Carcinogenesis ,Oncology and carcinogenesis - Abstract
BackgroundRecent trends of hepatocellular carcinoma (HCC) mortality and outcome remain unknown in the United States. We investigated the recent trends of primary liver cancer (excluding intrahepatic cholangiocarcinoma) mortality and HCC stage, treatment, and overall survival (OS) in the United States.MethodsThe National Center for Health Statistics Database was analyzed to investigate the trend of primary liver cancer mortality. We analyzed the Surveillance, Epidemiology, and End Results 18 Database to assess the temporal trend of tumor size, stage, treatment, and OS of HCC. We investigated the association between HCC diagnosis year and OS using Cox regression analysis. All statistical tests were 2-sided.ResultsDuring 2000-2018, liver cancer mortality rates increased until 2013, plateaued during 2013-2016 (annual percent change = 0.1%/y, 95% confidence interval [CI] = -2.1%/y to 2.4%/y, P = .92), and started to decline during 2016-2018 (annual percent change = -1.5%/y, 95% CI = -3.2%/y to 0.2%/y, P = .08). However, mortality continues to increase in American Indian and Alaska Native, individuals aged 65 years or older, and in 33 states. There was a 0.61% (95% CI = 0.53% to 0.69%, P
- Published
- 2021
14. Amanita Mushroom Toxin Poisoning in Los Angeles County
- Author
-
Jobin, Parker G., Stewart, Connor, Vipani, Aarshi, Perez-Alvarez, Ingrid, Pepkowitz, Samuel, Klapper, Ellen, Berg, Anders, Stillman, Kaytlena, Torbati, Sam, Kuo, Alexander, Trivedi, Hirsh, Yang, Ju Dong, Steinberger, Jonathan, Van Allan, Richard J., Friedman, Oren, Cardoza, Kathryn, and Ayoub, Walid S.
- Published
- 2024
- Full Text
- View/download PDF
15. Traditional Chinese Medicine, Cordyceps, Related to Hepatoportal Sclerosis
- Author
-
Kaur, Bhupinder, Vipani, Aarshi, Trivedi, Hirsh, Kuo, Alexander, Guindi, Maha, Yang, Ju Dong, and Ayoub, Walid S.
- Published
- 2023
- Full Text
- View/download PDF
16. Covalent Chemistry‐Mediated Multimarker Purification of Circulating Tumor Cells Enables Noninvasive Detection of Molecular Signatures of Hepatocellular Carcinoma
- Author
-
Sun, Na, Lee, Yi‐Te, Kim, Minhyung, Wang, Jasmine J, Zhang, Ceng, Teng, Pai‐Chi, Qi, Dongping, Zhang, Ryan Y, Tran, Benjamin V, Lee, Yue Tung, Ye, Jinglei, Palomique, Juvelyn, Nissen, Nicholas N, Han, Steven‐Huy B, Sadeghi, Saeed, Finn, Richard S, Saab, Sammy, Busuttil, Ronald W, Posadas, Edwin M, Liang, Li, Pei, Renjun, Yang, Ju Dong, You, Sungyong, Agopian, Vatche G, Tseng, Hsian‐Rong, and Zhu, Yazhen
- Subjects
Digestive Diseases ,Genetics ,Prevention ,Rare Diseases ,Liver Disease ,Biotechnology ,Cancer ,Clinical Research ,Liver Cancer ,4.1 Discovery and preclinical testing of markers and technologies ,Detection ,screening and diagnosis ,Good Health and Well Being ,circulating tumor cells ,click chemistry ,hepatocellular carcinoma ,nanosubstrate ,transcriptome profiling - Abstract
Transcriptomic profiling of tumor tissues introduces a large database, which has led to improvements in the ability of cancer diagnosis, treatment, and prevention. However, performing tumor transcriptomic profiling in the clinical setting is very challenging since the procurement of tumor tissues is inherently limited by invasive sampling procedures. Here, we demonstrated the feasibility of purifying hepatocellular carcinoma (HCC) circulating tumor cells (CTCs) from clinical patient samples with improved molecular integrity using Click Chips in conjunction with a multimarker antibody cocktail. The purified CTCs were then subjected to mRNA profiling by NanoString nCounter platform, targeting 64 HCC-specific genes, which were generated from an integrated data analysis framework with 8 tissue-based prognostic gene signatures from 7 publicly available HCC transcriptomic studies. After bioinformatics analysis and comparison, the HCC CTC-derived gene signatures showed high concordance with HCC tissue-derived gene signatures from TCGA database, suggesting that HCC CTCs purified by Click Chips could enable the translation of HCC tissue molecular profiling into a noninvasive setting.
- Published
- 2021
17. Multi-Center Analysis of Liver Transplantation for Combined Hepatocellular Carcinoma-Cholangiocarcinoma Liver Tumors
- Author
-
Dageforde, Leigh Anne, Vachharajani, Neeta, Tabrizian, Parissa, Agopian, Vatche, Halazun, Karim, Maynard, Erin, Croome, Kristopher, Nagorney, David, Hong, Johnny C, Lee, David, Ferrone, Cristina, Baker, Erin, Jarnagin, William, Hemming, Alan, Schnickel, Gabriel, Kimura, Shoko, Busuttil, Ronald, Lindemann, Jessica, Florman, Sander, Holzner, Matthew L, Srouji, Rami, Najjar, Marc, Yohanathan, Lavanya, Cheng, Jane, Amin, Hiral, Rickert, Charles A, Yang, Ju Dong, Kim, Joohyun, Pasko, Jennifer, Chapman, William C, and Majella Doyle, Maria B
- Subjects
Rare Diseases ,Chronic Liver Disease and Cirrhosis ,Cancer ,Organ Transplantation ,Digestive Diseases - (Gallbladder) ,Clinical Trials and Supportive Activities ,Prevention ,Digestive Diseases ,Liver Cancer ,Liver Disease ,Transplantation ,Clinical Research ,Aged ,Carcinoma ,Hepatocellular ,Cholangiocarcinoma ,Disease-Free Survival ,Hepatectomy ,Humans ,Kaplan-Meier Estimate ,Liver Neoplasms ,Liver Transplantation ,Male ,Middle Aged ,Neoplasm Recurrence ,Local ,Neoplasms ,Complex and Mixed ,Retrospective Studies ,Tumor Burden ,Clinical Sciences ,Surgery - Abstract
BackgroundCombined hepatocellular-cholangiocarcinoma liver tumors (cHCC-CCA) with pathologic differentiation of both hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma within the same tumor are not traditionally considered for liver transplantation due to perceived poor outcomes. Published results are from small cohorts and single centers. Through a multicenter collaboration, we performed the largest analysis to date of the utility of liver transplantation for cHCC-CCA.Study designLiver transplant and resection outcomes for HCC (n = 2,998) and cHCC-CCA (n = 208) were compared in a 12-center retrospective review (2009 to 2017). Pathology defined tumor type. Tumor burden was based on radiologic Milan criteria at time of diagnosis and applied to cHCC-CCA for uniform analysis. Kaplan-Meier survival curves and log-rank test were used to determine overall survival and disease-free survival. Cox regression was used for multivariate survival analysis.ResultsLiver transplantation for cHCC-CCA (n = 67) and HCC (n = 1,814) within Milan had no significant difference in overall survival (5-year cHCC-CCA 70.1%, HCC 73.4%, p = 0.806), despite higher cHCC-CCA recurrence rates (23.1% vs 11.5% 5 years, p
- Published
- 2021
18. MRI-AST (MAST) Score Accurately Predicts Major Adverse Liver Outcome, Hepatocellular Carcinoma, Liver Transplant, and Liver-Related Death
- Author
-
Truong, Emily, Gornbein, Jeffrey A., Yang, Ju Dong, Noureddin, Nabil, Harrison, Stephen A., Alkhouri, Naim, and Noureddin, Mazen
- Published
- 2023
- Full Text
- View/download PDF
19. OS-055 Defining the thresholds for alcohol intake on the risk of liver-related mortality in people with metabolic risk factors
- Author
-
Kim, Hyunseok, primary, Kirsch, Polly, additional, Yeo, Yee Hui, additional, Ayoub, Walid S, additional, Kuo, Alexander, additional, Pandyarajan, Vijay, additional, Trivedi, Hirsch, additional, Vipani, Aarshi, additional, Wang, Yun, additional, Seki, Ekihiro, additional, Pandol, Stephen, additional, Li, Debiao, additional, Lu, Shelly C., additional, and Yang, Ju Dong, additional
- Published
- 2024
- Full Text
- View/download PDF
20. LBO-006 A prospective, blinded, multicenter U.S. evaluation of a multianalyte blood-based test for the detection of hepatocellular carcinoma (HCC) in patients with cirrhosis
- Author
-
Taggart, David, primary, Mahajan, Shivani, additional, Gallant, Maxime, additional, Pinkoviezky, Itai, additional, Xu, Jianfeng, additional, Sorg, Allison, additional, Roberts, Curt, additional, Slinkov, Dmitri, additional, Gorospe, Emmanuel, additional, Mubarak, Abdullah, additional, Bhandari, Bal Raj, additional, Freilich, Bradley, additional, Gunn, Nadege, additional, Yang, Ju Dong, additional, Smith, John, additional, Younes, Ziad H., additional, Cabrera, Roniel, additional, Aguilar, Humberto, additional, Li, Wei, additional, Van Etten, Richard, additional, and Nguyen, Mindie, additional
- Published
- 2024
- Full Text
- View/download PDF
21. TOP-063 The efficacy of Glucagon-like Peptide-1 receptor agonists in patients with compensated cirrhosis and obesity
- Author
-
Han Ng, Wee, primary, Hui Yeo, Yee, additional, Singal, Amit, additional, Parikh, Neehar D., additional, Kuo, Alexander, additional, Kim, Hyunseok, additional, Wang, Yun, additional, Trivedi, Hirsch, additional, Rich, Nicole, additional, Samaan, Jamil, additional, S Ayoub, Walid, additional, Ma, Kevin, additional, and Yang, Ju Dong, additional
- Published
- 2024
- Full Text
- View/download PDF
22. Detection of Circulating Tumor Cells and Their Implications as a Biomarker for Diagnosis, Prognostication, and Therapeutic Monitoring in Hepatocellular Carcinoma
- Author
-
Ahn, Joseph C, Teng, Pai‐Chi, Chen, Pin‐Jung, Posadas, Edwin, Tseng, Hsian‐Rong, Lu, Shelly C, and Yang, Ju Dong
- Subjects
Clinical Research ,Rare Diseases ,Liver Disease ,Cancer ,Digestive Diseases ,Liver Cancer ,Biotechnology ,4.1 Discovery and preclinical testing of markers and technologies ,Detection ,screening and diagnosis ,4.2 Evaluation of markers and technologies ,Good Health and Well Being ,Biomarkers ,Tumor ,Carcinoma ,Hepatocellular ,Epithelial Cell Adhesion Molecule ,Humans ,Liquid Biopsy ,Liver Neoplasms ,Neoplastic Cells ,Circulating ,Prognosis ,Medical Biochemistry and Metabolomics ,Clinical Sciences ,Immunology ,Gastroenterology & Hepatology - Abstract
Hepatocellular carcinoma (HCC) is among the leading causes of worldwide cancer-related morbidity and mortality. Poor prognosis of HCC is attributed primarily to tumor presentation at an advanced stage when there is no effective treatment to achieve the long term survival of patients. Currently available tests such as alpha-fetoprotein have limited accuracy as a diagnostic or prognostic biomarker for HCC. Liver biopsy provides tissue that can reveal tumor biology but it is not used routinely due to its invasiveness and risk of tumor seeding, especially in early-stage patients. Liver biopsy is also limited in revealing comprehensive tumor biology due to intratumoral heterogeneity. There is a clear need for new biomarkers to improve HCC detection, prognostication, prediction of treatment response, and disease monitoring with treatment. Liquid biopsy could be an effective method of early detection and management of HCC. Circulating tumor cells (CTCs) are cancer cells in circulation derived from the original tumor or metastatic foci, and their measurement by liquid biopsy represents a great potential in facilitating the implementation of precision medicine in patients with HCC. CTCs can be detected by a simple peripheral blood draw and potentially show global features of tumor characteristics. Various CTC detection platforms using immunoaffinity and biophysical properties have been developed to identify and capture CTCs with high efficiency. Quantitative abundance of CTCs, as well as biological characteristics and genomic heterogeneity among the CTCs, can predict disease prognosis and response to therapy in patients with HCC. This review article will discuss the currently available technologies for CTC detection and isolation, their utility in the clinical management of HCC patients, their limitations, and future directions of research.
- Published
- 2021
23. Comparison of Surgical Resection and Systemic Treatment for Hepatocellular Carcinoma with Vascular Invasion: National Cancer Database Analysis
- Author
-
Govalan, Rajalakshmi, Lauzon, Marie, Luu, Michael, Ahn, Joseph C, Kosari, Kambiz, Todo, Tsuyoshi, Kim, Irene K, Noureddin, Mazen, Kuo, Alexander, Walid, Ayoub S, Sundaram, Vinay, Lu, Shelly C, Roberts, Lewis R, Singal, Amit G, Heimbach, Julie K, Agopian, Vatche G, Nissen, Nicholas, and Yang, Ju Dong
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Oncology and Carcinogenesis ,Digestive Diseases ,Patient Safety ,Cancer ,Liver Cancer ,Rare Diseases ,Liver Disease ,6.1 Pharmaceuticals ,Evaluation of treatments and therapeutic interventions ,6.4 Surgery ,Hepatocellular carcinoma ,Vascular invasion ,Surgical resection ,Prognosis - Abstract
IntroductionSmall studies from outside of the USA suggest excellent outcomes after surgical resection for hepatocellular carcinoma (HCC) with vascular invasion. The study aims to (1) compare overall survival after surgical resection and systemic therapy among patients with HCC and vascular invasion and (2) determine factors associated with receipt of surgical resection in a US population.MethodsHCC patients with AJCC clinical TNM stage 7th T3BN0M0 diagnosed between 2010 and 2017 from the National Cancer Database were analyzed. Cox and logistic regression analyses identified factors associated with overall survival and receipt of surgical resection.ResultsOf 11,259 patients with T3BN0M0 HCC, 325 (2.9%) and 4,268 (37.9%) received surgical resection and systemic therapy, respectively. In multivariable analysis, surgical resection was associated with improved survival compared to systemic therapy (adjusted hazard ratio: 0.496, 95% confidence interval: 0.426-0.578) with a median survival of 21.4 and 8.1 months, respectively. Superiority of surgical resection was observed in noncirrhotic and cirrhotic subgroups and propensity score matching and inverse probability of treatment weighting adjusted analysis. Asians were more likely to receive surgical resection, whereas Charlson comorbidity ≥3, elevated alpha-fetoprotein, smaller tumor size, care in a community cancer program, and the South or West region were associated with a lower likelihood of surgical resection.ConclusionHCC patients with vascular invasion may benefit from surgical resection compared to systemic therapies. Demographic and clinical features of HCC patients and region and type of treating facility were associated with surgical resection versus systemic treatment.
- Published
- 2021
24. The Role of Extracellular Vesicles in Disease Progression and Detection of Hepatocellular Carcinoma
- Author
-
Lee, Yi-Te, Tran, Benjamin V, Wang, Jasmine J, Liang, Icy Y, You, Sungyong, Zhu, Yazhen, Agopian, Vatche G, Tseng, Hsian-Rong, and Yang, Ju Dong
- Subjects
Biomedical and Clinical Sciences ,Oncology and Carcinogenesis ,Digestive Diseases ,Hepatitis ,Liver Cancer ,Prevention ,Liver Disease ,Rare Diseases ,Cancer ,Clinical Research ,Good Health and Well Being ,hepatocellular carcinoma ,extracellular vesicles ,disease progression ,cancer detection ,biomarker ,liquid biopsy ,Oncology and carcinogenesis - Abstract
Hepatocellular carcinoma (HCC) is the most common primary liver malignancy and one of the leading causes of cancer-related death worldwide. Despite the improvements in surveillance and treatment, the prognosis of HCC remains poor. Extracellular vesicles (EVs) are a heterogeneous group of phospholipid bilayer-enclosed particles circulating in the bloodstream and mediating intercellular communication. Emerging studies have shown that EVs play a crucial role in regulating the proliferation, immune escape, and metastasis of HCC. In addition, because EVs are present in the circulation at relatively early stages of disease, they are getting attention as an attractive biomarker for HCC detection. Over the past decade, dedicated efforts have been made to isolate EVs more efficiently and make them useful tools in different clinical settings. In this review article, we provide an overview of the EVs isolation methods and highlight the role of EVs as mediators in the pathogenesis and progression of HCC. Lastly, we summarize the potential applications of EVs in early-stage HCC detection.
- Published
- 2021
25. Beyond the Checkpoint: Severe Axitinib-induced Liver Injury
- Author
-
Yeo, Yee Hui, Ayoub, Walid, Yang, Ju Dong, Kuo, Alexander, and Trivedi, Hirsh D.
- Published
- 2023
- Full Text
- View/download PDF
26. Purification of HCC-specific extracellular vesicles on nanosubstrates for early HCC detection by digital scoring.
- Author
-
Sun, Na, Lee, Yi-Te, Zhang, Ryan Y, Kao, Rueihung, Teng, Pai-Chi, Yang, Yingying, Yang, Peng, Wang, Jasmine J, Smalley, Matthew, Chen, Pin-Jung, Kim, Minhyung, Chou, Shih-Jie, Bao, Lirong, Wang, Jing, Zhang, Xinyue, Qi, Dongping, Palomique, Juvelyn, Nissen, Nicolas, Han, Steven-Huy B, Sadeghi, Saeed, Finn, Richard S, Saab, Sammy, Busuttil, Ronald W, Markovic, Daniela, Elashoff, David, Yu, Hsiao-Hua, Li, Huiying, Heaney, Anthony P, Posadas, Edwin, You, Sungyong, Yang, Ju Dong, Pei, Renjun, Agopian, Vatche G, Tseng, Hsian-Rong, and Zhu, Yazhen
- Subjects
Humans ,Carcinoma ,Hepatocellular ,Liver Neoplasms ,Liver Cirrhosis ,Disease Progression ,Dimethylpolysiloxanes ,RNA ,Messenger ,Diagnosis ,Differential ,Neoplasm Staging ,Microfluidic Analytical Techniques ,Case-Control Studies ,ROC Curve ,Reverse Transcriptase Polymerase Chain Reaction ,Nanostructures ,Computer Simulation ,Aged ,Middle Aged ,Female ,Male ,Nanowires ,Early Detection of Cancer ,Lab-On-A-Chip Devices ,Hep G2 Cells ,Click Chemistry ,Extracellular Vesicles ,Biomarkers ,Tumor ,Liquid Biopsy ,Computational Chemistry - Abstract
We report a covalent chemistry-based hepatocellular carcinoma (HCC)-specific extracellular vesicle (EV) purification system for early detection of HCC by performing digital scoring on the purified EVs. Earlier detection of HCC creates more opportunities for curative therapeutic interventions. EVs are present in circulation at relatively early stages of disease, providing potential opportunities for HCC early detection. We develop an HCC EV purification system (i.e., EV Click Chips) by synergistically integrating covalent chemistry-mediated EV capture/release, multimarker antibody cocktails, nanostructured substrates, and microfluidic chaotic mixers. We then explore the translational potential of EV Click Chips using 158 plasma samples of HCC patients and control cohorts. The purified HCC EVs are subjected to reverse-transcription droplet digital PCR for quantification of 10 HCC-specific mRNA markers and computation of digital scoring. The HCC EV-derived molecular signatures exhibit great potential for noninvasive early detection of HCC from at-risk cirrhotic patients with an area under receiver operator characteristic curve of 0.93 (95% CI, 0.86 to 1.00; sensitivity = 94.4%, specificity = 88.5%).
- Published
- 2020
27. Increase in Alcoholic Hepatitis as an Etiology for Liver Transplantation in the United States: A 2004–2018 Analysis
- Author
-
Noureddin, Nabil, Yang, Ju Dong, Alkhouri, Naim, Noreen, Samantha M, Toll, Alice E, Todo, Tsuyoshi, Ayoub, Walid, Kuo, Alexander, Voidonikolas, Georgios, Kotler, Honore G, Pelphrey, Michalyn D, Durand, Brenda J, Kosari, Kambiz, Brennan, Todd V, Kim, Irene, Klein, Andrew S, Seki, Ekihiro, Nissen, Nicholas N, Lu, Shelly C, Sundaram, Vinay, and Noureddin, Mazen
- Subjects
Transplantation ,Organ Transplantation ,Substance Misuse ,Hepatitis ,Digestive Diseases ,Liver Disease ,Alcoholism ,Alcohol Use and Health ,Chronic Liver Disease and Cirrhosis ,Good Health and Well Being - Abstract
BackgroundChanging opinions on the alcohol abstinence requirement have led to increased liver transplantation (LT) for alcoholic hepatitis (AH). We aimed to determine the trend in LT for AH in the United States and overall and graft survival rates.MethodsAdult liver-alone and liver-kidney registrations added to the Organ Procurement and Transplantation Network waiting list between 2004 and 2018 were divided into 3 periods (2004-2009, 2010-2013, 2014-2018). Kaplan-Meier survival models illustrated patient and graft survival.ResultsBetween 2004 and 2018, 529 AH patients were registered for and 254 received LT. By periods, 116, 73, and 340 patients were registered for and 49, 17, and 188 patients received LT, respectively, indicating a increase in LT for AH from 2014 to 2018. Yearly registrants from 2014 to 2018 were 32, 47, 51, 70, and 140, and recipients were 16, 24, 24, 38, and 88, respectively, indicating increases of 338% and 450% in registrants and recipients, respectively, since 2014. AH patients had the highest 1- and 3-year posttransplant survival (93.2% and 87.3%, respectively) and graft survival (90.4% and 84.8%, respectively) comparing to other LT recipients.ConclusionsLT for AH in the United States is at an all-time high with an increased overall patient and graft survival.
- Published
- 2020
28. High Neutrophil–Lymphocyte Ratio and Delta Neutrophil–Lymphocyte Ratio Are Associated with Increased Mortality in Patients with Hepatocellular Cancer
- Author
-
Rich, Nicole E., Parvathaneni, Aarthi, Sen, Ahana, Odewole, Mobolaji, Arroyo, Ana, Mufti, Arjmand R., Kerr, Thomas A., Grant, Lafaine, Tujios, Shannan R., Mayo, Marlyn J., Lee, William M., Yang, Ju Dong, Yokoo, Takeshi, Gopal, Purva, Hoshida, Yujin, Zhu, Hao, Yopp, Adam C., Marrero, Jorge A., and Singal, Amit G.
- Published
- 2022
- Full Text
- View/download PDF
29. Unveiling Etiology-Specific Blood Biomarkers in Hepatocellular Carcinoma: A Gateway to Personalized Medicine
- Author
-
Ahn, Joseph C., primary and Yang, Ju Dong, additional
- Published
- 2024
- Full Text
- View/download PDF
30. Role of biomarkers in the diagnosis and management of HCC
- Author
-
Alhasan, Mohammed, primary, Mehta, Neil, additional, Yang, Ju Dong, additional, and Singal, Amit G., additional
- Published
- 2024
- Full Text
- View/download PDF
31. MASLD/MetALD and mortality in individuals with any cardio-metabolic risk factor: a population based study with 26.7 years of follow-up
- Author
-
Kwak, Minsun, primary, Kim, Hyun-seok, additional, Jiang, Zhenghui Gordon, additional, Yeo, Yee Hui, additional, Trivedi, Hirsh D., additional, Noureddin, Mazen, additional, and Yang, Ju Dong, additional
- Published
- 2024
- Full Text
- View/download PDF
32. Alpha-fetoprotein: Past, present, and future
- Author
-
Yeo, Yee Hui, primary, Lee, Yi-Te, additional, Tseng, Hsian-Rong, additional, Zhu, Yazhen, additional, You, Sungyong, additional, Agopian, Vatche G., additional, and Yang, Ju Dong, additional
- Published
- 2024
- Full Text
- View/download PDF
33. Incidence of liver cancer in young adults according to the global burden of disease database 2019
- Author
-
Danpanichkul, Pojsakorn, primary, Aboona, Majd B., additional, Sukphutanan, Banthoon, additional, Kongarin, Siwanart, additional, Duangsonk, Kwanjit, additional, Ng, Cheng Han, additional, Muthiah, Mark D., additional, Huang, Daniel Q., additional, Seko, Yuya, additional, Díaz, Luis Antonio, additional, Arab, Juan Pablo, additional, Yang, Ju Dong, additional, Chen, Vincent L., additional, Kim, Donghee, additional, Noureddin, Mazen, additional, Liangpunsakul, Suthat, additional, and Wijarnpreecha, Karn, additional
- Published
- 2024
- Full Text
- View/download PDF
34. Starting the journey: Understanding the roles of complement proteins in liver diseases through mendelian randomization
- Author
-
Rezaee-Zavareh, Mohammad Saeid, primary, Kim, Naomy, additional, and Yang, Ju Dong, additional
- Published
- 2024
- Full Text
- View/download PDF
35. Current status of hepatocellular carcinoma detection: screening strategies and novel biomarkers
- Author
-
Ayoub, Walid S, Steggerda, Justin, Yang, Ju Dong, Kuo, Alexander, Sundaram, Vinay, and Lu, Shelly C
- Subjects
Rare Diseases ,Clinical Research ,Hepatitis ,Liver Cancer ,Biomedical Imaging ,Digestive Diseases ,Prevention ,Cancer ,Liver Disease ,4.1 Discovery and preclinical testing of markers and technologies ,4.2 Evaluation of markers and technologies ,Detection ,screening and diagnosis ,Good Health and Well Being ,biomarkers ,CT ,HCC ,liquid biopsy ,MRI ,surveillance ,ultrasound - Abstract
Hepatocellular carcinoma (HCC) remains a major cause of cancer-related mortality worldwide. Delayed diagnosis is a major factor responsible for the poor prognosis of HCC. Several advances have been made in the field of liver imaging with the use of novel imaging contrasts, improving current imaging techniques with contrast-enhanced computed tomography (CT) and magnetic resonance imaging (MRI), introduction of new technologies such as contrast liver ultrasound, and development of novel biomarkers with the goal of early detection of HCC and improving outcomes of patients with HCC. This review focuses on current surveillance strategies and development of biomarkers with the goal of early detection of HCC.
- Published
- 2019
36. Rare Liver Tumors
- Author
-
Navin, Patrick J., Yang, Ju Dong, Torbenson, Michael S., Venkatesh, Sudhakar K., Roberts, Lewis R., editor, Yang, Ju Dong, editor, and Venkatesh, Sudhakar K., editor
- Published
- 2020
- Full Text
- View/download PDF
37. Cachexia is Prevalent in Patients With Hepatocellular Carcinoma and Associated With Worse Prognosis
- Author
-
Rich, Nicole E., Phen, Samuel, Desai, Nirali, Mittal, Sukul, Yopp, Adam C., Yang, Ju Dong, Marrero, Jorge A., Iyengar, Puneeth, Infante, Rodney E., and Singal, Amit G.
- Published
- 2022
- Full Text
- View/download PDF
38. Decreasing Trend of Serum α-Fetoprotein Level in Hepatocellular Carcinoma
- Author
-
Vipani, Aarshi, Lauzon, Marie, Luu, Michael, Roberts, Lewis R., Singal, Amit G., and Yang, Ju Dong
- Published
- 2022
- Full Text
- View/download PDF
39. Provider Attitudes Toward Risk-Based Hepatocellular Carcinoma Surveillance in Patients With Cirrhosis in the United States
- Author
-
Kim, Nicole J., Rozenberg-Ben-Dror, Karine, Jacob, David A., Rich, Nicole E., Singal, Amit G., Aby, Elizabeth S., Yang, Ju Dong, Nguyen, Veronica, Pillai, Anjana, Fuchs, Michael, Moon, Andrew M., Shroff, Hersh, Agarwal, Parul D., Perumalswami, Ponni, Chandna, Shaun, Zhou, Kali, Patel, Yuval A., Latt, Nyan L., Wong, Robert, Duarte-Rojo, Andres, Lindenmeyer, Christina C., Frenette, Catherine, Ge, Jin, Mehta, Neil, Yao, Francis, Benhammou, Jihane N., Bloom, Patricia P., Leise, Michael, Kim, Hyun-seok, Levy, Cynthia, Barnard, Abbey, Khalili, Mandana, and Ioannou, George N.
- Published
- 2022
- Full Text
- View/download PDF
40. Global epidemiology of alcohol‐associated liver disease in adolescents and young adults.
- Author
-
Danpanichkul, Pojsakorn, Chen, Vincent L., Tothanarungroj, Primrose, Kaewdech, Apichat, Kanjanakot, Yatawee, Fangsaard, Panisara, Wattanachayakul, Phuuwadith, Duangsonk, Kwanjit, Kongarin, Siwanart, Yang, Ju Dong, Wong, Robert J., Noureddin, Mazen, Díaz, Luis Antonio, Arab, Juan Pablo, Liangpunsakul, Suthat, and Wijarnpreecha, Karn
- Abstract
Summary: Background and Aims: The objective of the study was to analyse the prevalence, incidence, and death of alcohol‐associated liver disease (ALD) among adolescents and young adults globally, continentally, and nationally, focusing on trends over time. Methods: The study analysed data from the Global Burden of Disease (GBD) study between 2000 and 2019. It examined ALD's prevalence, incidence, and death in adolescents and young adults aged 15–29, segmented by region, nation, and sociodemographic index. The analysis utilised Joinpoint regression modelling to calculate the annual per cent change (APC) in the rate of these parameters over time. Results: In 2019, there were 281,450 ALD prevalences, 18,930 incidences, and 3190 deaths among adolescents and young adults globally. From 2000 to 2019, the age‐adjusted prevalence rate per 100,000 increased in the 25–29 age group (APC: +0.6%, p = 0.003), remained stable among ages 20–24 (p = 0.302) and ages 15–19 (p = 0.160). Prevalence increased significantly from age 15–19 to 20–24 (19‐fold increase) and from age 20–24 to 25–29 (2.5‐fold increase). ALD prevalence rates increased in all age groups in adolescents and young adults in Africa and the Eastern Mediterranean region. Around three‐quarters of countries and territories experienced an increase in ALD incidence rates in young adults. Conclusion: Over two decades, the burden of ALD among adolescents and young adults has increased globally. The study emphasises the importance of public health policies aimed at reducing alcohol consumption and preventing ALD among younger populations. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
41. Incidence and Long-Term Outcomes of Biliary Tract Cancers in Olmsted County, Minnesota from 1976 to 2018.
- Author
-
Nwankwo Jr., Eugene C., Guta, Amerti, Cao, Scarlett S., Yang, Ju Dong, Abdalla, Abubaker, Taha, Wesam, Larson, Joseph J., Yin, Jun, Gores, Gregory J., Cleary, Sean P., and Roberts, Lewis R.
- Subjects
BILE duct tumors ,POISSON distribution ,GALLBLADDER tumors ,SURVIVAL rate ,RESEARCH funding ,SEX distribution ,CHOLANGIOCARCINOMA ,RETROSPECTIVE studies ,AGE distribution - Abstract
Simple Summary: Biliary tract cancers, which include cholangiocarcinoma, gallbladder, and ampulla of Vater cancers, are a significant health concern due to their increasing incidence and poor survival rates. Using data from the Rochester Epidemiology Project, this study tracks changes in incidence and survival rates among residents aged 20 and over in Olmsted County, Minnesota from 1976 to 2018. The findings illustrate a rise in overall biliary tract cancers from 6.53 cases to 10.25 cases per 100,000 person-years between 1976 and 2018 (p = 0.004). The incidence of intrahepatic cholangiocarcinoma has significantly increased from 0.25 to 3.93 per 100,000 person-years over the four decades, with a more pronounced increase observed in males, while gallbladder cancer incidence has decreased among women. Despite improvements in median survival times from 4.2 months to 10.8 months over the four decades (p = 0.019), the overall prognosis remains very poor. This study highlights the evolving epidemiology of these cancers and the critical need for enhanced diagnostic and treatment strategies to improve patient outcomes. Biliary tract cancers, including cholangiocarcinoma, gallbladder, and ampulla of Vater cancers, rank second among hepatobiliary cancers, known for their poor prognoses. The United States has witnessed a notable increase in intrahepatic cholangiocarcinoma incidence. This study examines the incidence and survival outcomes of biliary tract cancers in Olmsted County, Minnesota from 1976 to 2018. Using data from the Rochester Epidemiology Project (REP), residents aged 20 and above were analyzed across four eras. Incidence rates were calculated and adjusted for age and sex, and temporal trends were assessed using Poisson regression. Intrahepatic cholangiocarcinoma exhibited a significant escalation in incidence rates over time, while gallbladder cancers showed a decline among women. Median survival times for biliary tract cancers notably improved. These findings confirm the rising incidence of intrahepatic cholangiocarcinoma and suggest improving survival rates. Nevertheless, the overall prognosis for biliary tract cancers remains very poor, emphasizing the continual need for enhanced management strategies and further research. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
42. Food Insecurity in Hispanic Populations Is Associated with an Increased Risk of Hepatic Steatosis: A Nationally Representative Study.
- Author
-
Niezen, Sebastian, Goyes, Daniela, Vipani, Aarshi, Yang, Ju Dong, Ayoub, Walid S., Kuo, Alexander, Long, Michelle T., and Trivedi, Hirsh D.
- Subjects
FATTY liver ,FOOD security ,NON-alcoholic fatty liver disease ,HEALTH & Nutrition Examination Survey ,DIETARY patterns - Abstract
Introduction: The Hispanic population in the US faces a higher risk of nonalcoholic fatty liver disease (NAFLD). Multiple factors influence this risk, including genetics, environmental factors, and socioeconomic statuses. Inadequate access to nutritious foods, or food insecurity, is prevalent among Hispanic individuals and poses a metabolic risk for both the onset and development of NAFLD. Materials and Methods: We utilized the National Health and Nutrition Examination Survey (NHANES) 2017–2020 pre-pandemic data to analyze the association between Hispanic ethnicity, hepatic steatosis, fibrosis, and food insecurity. Vibration-controlled transient elastography (VCTE) was employed to assess liver stiffness (LSM) and controlled attenuation parameter (CAP) scores to determine fibrosis and steatosis, respectively. Linear and ordinal logistic regression models were applied to their continuous, log-transformed, and categorical forms, adjusting for demographics, metabolic comorbidities, and socioeconomic factors. Models were subsequently stratified based on food security statuses. Results: A total of 7396 Hispanic participants were included in the study. Under multivariable analysis, Hispanic individuals had higher CAP scores (Beta-coefficient: 10.2 dB/m, 95% CI: 6.1–14.4 dB/m, p = 0.001)) vs. non-Hispanic individuals, without statistically significant differences in fibrosis. Food-insecure participants exhibited higher CAP scores than their food-secure counterparts. After stratification, a stronger association between Hispanic ethnicity and CAP scores was evident in the food-insecure group (Beta-coefficient: 11.8 dB/m, 95% CI: 4.4–19.3 dB/m, p = 0.003). Discussion: This study demonstrates the heightened risk of hepatic steatosis among individuals with Hispanic ancestry in the US. The risk is exacerbated by food insecurity, particularly for Hispanic individuals. The contribution is linked to the dietary habits in this population that lead to metabolic risk factors associated with hepatic steatosis. Considering the rising prevalence of NAFLD and food insecurity, interventions focusing on nutritional support and healthcare access among this population could mitigate these burdens. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
43. Blood Salvage and Autotransfusion With Single Leukoreduction Does Not Increase the Risk of Tumor Recurrence After Liver Transplantation for Advanced Hepatocellular Carcinoma
- Author
-
Kwon, Ji-Hye, Han, Sangbin, Kim, Doyeon, Kuk, Joon Hee, Cho, Hyun, Kim, Seonwoo, Yang, Ju Dong, Kim, Chul, Kim, Jong Man, Choi, Gyu Sung, Joh, Jae-Won, Ko, Justin S., Gwak, Mi Sook, and Kim, Gaabsoo
- Published
- 2022
- Full Text
- View/download PDF
44. Artificial intelligence in liver cancer research: a scientometrics analysis of trends and topics
- Author
-
Rezaee-Zavareh, Mohammad Saeid, primary, Kim, Naomy, additional, Yeo, Yee Hui, additional, Kim, Hyunseok, additional, Lee, Jeong Min, additional, Sirlin, Claude B., additional, Taouli, Bachir, additional, Saouaf, Rola, additional, Wachsman, Ashley M., additional, Noureddin, Mazen, additional, Wang, Zhiping, additional, Moore, Jason, additional, Li, Debiao, additional, Singal, Amit G., additional, and Yang, Ju Dong, additional
- Published
- 2024
- Full Text
- View/download PDF
45. Antiviral Therapy Utilization and 10-Year Outcomes in Resected Hepatitis B Virus– and Hepatitis C Virus–Related Hepatocellular Carcinoma
- Author
-
Huang, Daniel Q., primary, Hoang, Joseph K., additional, Kamal, Rubayet, additional, Tsai, Pei-Chien, additional, Toyoda, Hidenori, additional, Yeh, Ming-Lun, additional, Yasuda, Satoshi, additional, Leong, Jennifer, additional, Maeda, Mayumi, additional, Huang, Chung-Feng, additional, Won Jun, Dae, additional, Ishigami, Masatoshi, additional, Tanaka, Yasuhito, additional, Uojima, Haruki, additional, Ogawa, Eiichi, additional, Abe, Hiroshi, additional, Hsu, Yao-Chun, additional, Tseng, Cheng-Hao, additional, Alsudaney, Manaf, additional, Yang, Ju Dong, additional, Yoshimaru, Yoko, additional, Suzuki, Takanori, additional, Liu, Joanne K., additional, Landis, Charles, additional, Dai, Chia-Yen, additional, Huang, Jee-Fu, additional, Chuang, Wan-Long, additional, Schwartz, Myron, additional, Dan, Yock Young, additional, Esquivel, Carlos, additional, Bonham, Andrew, additional, Yu, Ming-Lung, additional, and Nguyen, Mindie H., additional
- Published
- 2024
- Full Text
- View/download PDF
46. Primary liver cancer spectrum: current knowledge and the next steps
- Author
-
Rezaee-Zavareh, Mohammad Saeid, primary, Koltsova, Ekaterina K., additional, Hoshida, Yujin, additional, and Yang, Ju Dong, additional
- Published
- 2024
- Full Text
- View/download PDF
47. BALAD and BALAD-2 predict survival of hepatocellular carcinoma patients: a North American cohort study
- Author
-
Wongjarupong, Nicha, Negron-Ocasio, Gabriela M., Mara, Kristin C., Prasai, Kritika, Abdallah, Mohamed A., Ahn, Keun Soo, Yang, Ju Dong, Addissie, Benyam D., Giama, Nasra H., Harmsen, William S., Therneau, Terry M., and Roberts, Lewis R.
- Published
- 2021
- Full Text
- View/download PDF
48. Integrative Genomic Analysis of Cholangiocarcinoma Identifies Distinct IDH-Mutant Molecular Profiles
- Author
-
Farshidfar, Farshad, Zheng, Siyuan, Gingras, Marie-Claude, Newton, Yulia, Shih, Juliann, Robertson, A Gordon, Hinoue, Toshinori, Hoadley, Katherine A, Gibb, Ewan A, Roszik, Jason, Covington, Kyle R, Wu, Chia-Chin, Shinbrot, Eve, Stransky, Nicolas, Hegde, Apurva, Yang, Ju Dong, Reznik, Ed, Sadeghi, Sara, Pedamallu, Chandra Sekhar, Ojesina, Akinyemi I, Hess, Julian M, Auman, J Todd, Rhie, Suhn K, Bowlby, Reanne, Borad, Mitesh J, Network, The Cancer Genome Atlas, Akbani, Rehan, Allotey, Loretta K, Ally, Adrian, Alvaro, Domenico, Andersen, Jesper B, Appelbaum, Elizabeth L, Arora, Arshi, Balasundaram, Miruna, Balu, Saianand, Bardeesy, Nabeel, Bathe, Oliver F, Baylin, Stephen B, Beroukhim, Rameen, Berrios, Mario, Bodenheimer, Tom, Boice, Lori, Bootwalla, Moiz S, Bowen, Jay, Bragazzi, Maria Consiglia, Brooks, Denise, Cardinale, Vincenzo, Carlsen, Rebecca, Carpino, Guido, Carvalho, Andre L, Chaiteerakij, Roongruedee, Chandan, Vishal C, Cherniack, Andrew D, Chin, Lynda, Cho, Juok, Choe, Gina, Chuah, Eric, Chudamani, Sudha, Cibulskis, Carrie, Cordes, Matthew G, Crain, Daniel, Curley, Erin, De Rose, Agostino Maria, Defreitas, Timothy, Demchok, John A, Deshpande, Vikram, Dhalla, Noreen, Ding, Li, Evason, Kimberley, Felau, Ina, Ferguson, Martin L, Foo, Wai Chin, Franchitto, Antonio, Frazer, Scott, Fronick, Catrina C, Fulton, Lucinda A, Fulton, Robert S, Gabriel, Stacey B, Gardner, Johanna, Gastier-Foster, Julie M, Gaudio, Eugenio, Gehlenborg, Nils, Genovese, Giannicola, Gerken, Mark, Getz, Gad, Giama, Nasra H, Gibbs, Richard A, Giuliante, Felice, Grazi, Gian Luca, Hayes, D Neil, Hegde, Apurva M, and Heiman, David I
- Subjects
Liver Cancer ,Digestive Diseases ,Liver Disease ,Biotechnology ,Human Genome ,Genetics ,Cancer ,Rare Diseases ,Digestive Diseases - (Gallbladder) ,Adult ,Aged ,Aged ,80 and over ,Bile Duct Neoplasms ,Cholangiocarcinoma ,Chromatin ,DNA Methylation ,DNA-Binding Proteins ,Female ,Gene Expression Regulation ,Neoplastic ,Genomics ,Humans ,Isocitrate Dehydrogenase ,Liver ,Liver Neoplasms ,Male ,Middle Aged ,Mitochondria ,Mutation ,Nuclear Proteins ,Pancreatic Neoplasms ,Promoter Regions ,Genetic ,RNA ,Long Noncoding ,RNA ,Messenger ,Transcription Factors ,Cancer Genome Atlas Network ,ARID1A ,DNA methylation ,IDH ,RNA sequencing ,TCGA ,cholangiocarcinoma ,integrative genomics ,lncRNAs ,multi-omics ,whole exome ,Biochemistry and Cell Biology ,Medical Physiology - Abstract
Cholangiocarcinoma (CCA) is an aggressive malignancy of the bile ducts, with poor prognosis and limited treatment options. Here, we describe the integrated analysis of somatic mutations, RNA expression, copy number, and DNA methylation by The Cancer Genome Atlas of a set of predominantly intrahepatic CCA cases and propose a molecular classification scheme. We identified an IDH mutant-enriched subtype with distinct molecular features including low expression of chromatin modifiers, elevated expression of mitochondrial genes, and increased mitochondrial DNA copy number. Leveraging the multi-platform data, we observed that ARID1A exhibited DNA hypermethylation and decreased expression in the IDH mutant subtype. More broadly, we found that IDH mutations are associated with an expanded histological spectrum of liver tumors with molecular features that stratify with CCA. Our studies reveal insights into the molecular pathogenesis and heterogeneity of cholangiocarcinoma and provide classification information of potential therapeutic significance.
- Published
- 2017
49. Patient Sex, Reproductive Status, and Synthetic Hormone Use Associate With Histologic Severity of Nonalcoholic Steatohepatitis
- Author
-
Yang, Ju Dong, Abdelmalek, Manal F, Guy, Cynthia D, Gill, Ryan M, Lavine, Joel E, Yates, Katherine, Klair, Jagpal, Terrault, Norah A, Clark, Jeanne M, Unalp-Arida, Aynur, Diehl, Anna Mae, Suzuki, Ayako, Dasarathy, Srinivasan, Dasarathy, Jaividhya, Hawkins, Carol, McCullough, Arthur J, Pagadala, Mangesh, Pai, Rish, Sargent, Ruth, Bashir, Mustafa, Buie, Stephanie, Guy, Cynthia, Kigongo, Christopher, Pan, Yi-Ping, Piercy, Dawn, Chalasani, Naga, Cummings, Oscar W, Gawrieh, Samer, Ghabril, Marwan, Marri, Smitha, Ragozzino, Linda, Sandrasegaran, Kumar, Vuppalanchi, Raj, King, Debra, Osmack, Pat, Siegner, Joan, Stewart, Susan, Neuschwander-Tetri, Brent A, Torretta, Susan, Ang, Brandon, Behling, Cynthia, Bhatt, Archana, Loomba, Rohit, Middleton, Michael, Patton, Heather, Sirlin, Claude, Aouizerat, Bradley, Bass, Nathan M, Brandman, Danielle, Ferrell, Linda D, Gill, Ryan, Hameed, Bilal, Ramos, Claudia, Terrault, Norah, Ungermann, Ashley, Atla, Pradeep, Croft, Brandon, Garcia, Rebekah, Garcia, Sonia, Sheikh, Muhammad, Singh, Mandeep, Boyett, Sherry, Carucci, Laura, Contos, Melissa J, Kraft, Kenneth, Luketic, Velimir AC, Puri, Puneet, Sanyal, Arun J, Schlosser, Jolene, Siddiqui, Mohhamad S, Wolford, Ben, Ackermann, Sarah, Cooney, Shannon, Coy, David, Gelinas, Katie, Kowdley, Kris V, Lee, Maximillian, Pierce, Tracey, Mooney, Jody, Nelson, James E, Shaw, Cheryl, Siddique, Asma, Wang, Chia, Brunt, Elizabeth M, Fowler, Kathryn, Kleiner, David E, Grave, Gilman D, Doo, Edward C, Hoofnagle, Jay H, Robuck, Patricia R, Sherker, Averell, Belt, Patricia, Donithan, Michele, Hallinan, Erin, and Isaacson, Milana
- Subjects
Reproductive Medicine ,Biomedical and Clinical Sciences ,Clinical Sciences ,Digestive Diseases ,Liver Disease ,Contraception/Reproduction ,Prevention ,Hepatitis ,Estrogen ,Chronic Liver Disease and Cirrhosis ,Aging ,Good Health and Well Being ,Adolescent ,Adult ,Aged ,Cross-Sectional Studies ,Female ,Histocytochemistry ,Hormones ,Humans ,Male ,Menopause ,Middle Aged ,Non-alcoholic Fatty Liver Disease ,Reproduction ,Risk Factors ,Sex Factors ,United States ,Young Adult ,Gender Differences ,Fibrosis ,Risk Factor Analysis. ,Nonalcoholic Steatohepatitis Clinical Research Network ,Risk Factor Analysis ,Gastroenterology & Hepatology ,Clinical sciences - Abstract
Background & aimsSex and sex hormones can affect responses of patients with nonalcoholic fatty liver disease (NAFLD) to metabolic stress and development of hepatocyte injury and inflammation.MethodsWe collected data from 3 large U.S. studies of patients with NAFLD (between October 2004 and June 2013) to assess the association between histologic severity and sex, menopause status, synthetic hormone use, and menstrual abnormalities in 1112 patients with a histologic diagnosis of NAFLD. We performed logistic or ordinal logistic regression models, adjusting for covariates relevant to an increase of hepatic metabolic stress.ResultsPremenopausal women were at an increased risk of lobular inflammation, hepatocyte ballooning, and Mallory-Denk bodies than men and also at an increased risk of lobular inflammation and Mallory-Denk bodies than postmenopausal women (P < .01). Use of oral contraceptives was associated with an increased risk of lobular inflammation and Mallory-Denk bodies in premenopausal women, whereas hormone replacement therapy was associated with an increased risk of lobular inflammation in postmenopausal women (P < .05).ConclusionsBeing a premenopausal woman or a female user of synthetic hormones is associated with increased histologic severity of hepatocyte injury and inflammation among patients with NAFLD at given levels of hepatic metabolic stress.
- Published
- 2017
50. Integrative Genomic Analysis of Cholangiocarcinoma Identifies Distinct IDH-Mutant Molecular Profiles
- Author
-
Roberts, Lewis R, Farshidfar, Farshad, Zheng, Siyuan, Gingras, Marie-Claude, Newton, Yulia, Shih, Juliann, Robertson, A Gordon, Hinoue, Toshinori, Hoadley, Katherine A, Gibbs, Richard, Roszik, Jason, Covington, Kyle, Wu, Chia-Chin, Shinbrot, Eve, Stransky, Nicolas, Hegde, Apurva M, Yang, Ju Dong, Reznik, Ed, Sadeghi, Sara, Pedamallu, Chandra Sekhar, Ojesina, Akinyemi I, Hess, Julian, Auman, J Todd, Rhie, Suhn K, Bowlby, Reanne, Borad, Mitesh J, Stuart, Josh, Sander, Chris, Akbani, Rehan, Cherniack, Andrew D, Laird, Peter W, Deshpande, Vikram, Mounajjed, Taofic, Foo, Wai Chin, Torbenson, Michael, Kleiner, David E, Wheeler, David A, Mcree, Autumn J, Bathe, Oliver F, Andersen, Jesper B, Bardeesy, Nabeel, and Kwong, Lawrence N
- Subjects
Gastroenterology & Hepatology ,Medical Biochemistry and Metabolomics ,Clinical Sciences ,Immunology - Published
- 2016
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.